SciSparc Wins European Patent for its Core Technology
Portfolio Pulse from Benzinga Newsdesk
SciSparc Ltd. (NASDAQ:SPRC), a clinical-stage pharmaceutical company, has been granted a new patent by The European Patent Office. The patent, titled 'Combinations of Cannabinoids and N-Acylethanolamines', aligns with the company's objective to increase the safety of cannabinoids treatments while maintaining their therapeutic effects. The company has also been granted this patent in the United States, Japan, and Australia.
October 03, 2023 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The new patent granted to SciSparc Ltd. by The European Patent Office could potentially enhance the company's competitive edge in the pharmaceutical industry. The patent is also recognized in the US, Japan, and Australia, expanding the company's global reach.
The granting of a new patent to SciSparc Ltd. is a positive development for the company. Patents provide a competitive edge by protecting the company's innovations from being copied by competitors. This patent, which is also recognized in the US, Japan, and Australia, expands the company's global reach and could potentially lead to increased revenues in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100